26/07/2013

MPS IIIA: GENE THERAPY FOR BRAIN AND BODY (SANFILIPPO)

SciBX By Michael J. Haas, Senior Writer

Less than a year after reporting preclinical proof of concept for a systemically
delivered mucopolysaccharidosis IIIA gene therapy, researchers
at the Autonomous University of Barcelona have shown that intracerebral
delivery can substantially improve efficacy in the CNS and treat
symptoms in peripheral organs.1 ESTEVE., who partially funded the
work, is now raising funds to test the approach in the clinic.

To download the full article click the PDF

More information www.esteve.es/en/research-development

You may follow ESTEVE on Twitter via this link: twitter.com/esteve_news.

Last news

  • ESTEVE APPOINTS JORDI MUNTAÑOLA AS CHIEF COMMERCIAL OFFICER FOR EUROPE

    Jordi Muntañola will take on the leadership of all the pharmaceutical activities in Spain and Europe

    read more
  • POMPEU FABRA UNIVERSITY AND ESTEVE ARE TO INVESTIGATE NEW TARGETS FOR TREATING NEUROPATHIC PAIN

    The RIBOPAIN project aims to identify new therapeutic solutions for pain and to develop more effective drugs

    read more
  • ESTEVE ANNOUNCES A RESTRUCTURING OF ITS PHARMACEUTICAL ACTIVITY

    Esteve Pharmaceuticals submits a reduction in force (RIF) which will affect 103 jobs in Spain

    read more

Follow us at

This Website uses its own and third-party cookies to improve our services and analyse the user's browsing habits. If you continue browsing, we will consider you to have accepted their use. You can find more information by visiting our Cookies policy.